The story of one of the most famous quality measures -- percentage of patients with acute myocardial infarction who receive a prescription for beta-blockers within seven days of hospital discharge -- is an example of how people fit together. Beta-blockers are a class of drugs that block the effects of adrenaline and slow down the heart rate. In 1982, results from a randomized controlled trial found that administering beta-blockers after heart attacks cut patients’ death rate by an astounding 40 percent. The results were so conclusive for all types of patients that within two years, they had been written into medical textbooks and featured in both medical journals and mainstream news media. By the end of the decade, the medical profession at large had come to understand the importance of a veritable “silver bullet” for heart attack care.
And yet, by the mid-1990s, only 34 percent of patients received beta-blockers after heart attacks. The policy response was an expans